Related Experiment Videos
Factors associated with endometrial bleeding in continuous hormone replacement therapy
Wen-Yi Shau1, Ching-Chang Hsieh, T'sang-T'ang Hsieh
1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Menopause (New York, N.Y.)
|April 26, 2002
Summary
Postmenopausal women with shorter duration since last menstruation, thicker endometrium, and higher estradiol levels are at higher risk for endometrial bleeding during hormone replacement therapy.
Area of Science:
- Gynecology
- Reproductive Endocrinology
Background:
- Continuous hormone replacement therapy (HRT) is prescribed for menopausal symptom management.
- Endometrial bleeding is a potential side effect of HRT in postmenopausal women.
Purpose of the Study:
- To identify clinical and laboratory predictors of early endometrial bleeding in postmenopausal women on continuous HRT.
Main Methods:
- Prospective study of 55 postmenopausal women on conjugated estrogen and medroxyprogesterone acetate.
- Monitoring of bleeding episodes and assessment of postmenopausal duration, endometrial thickness, and serum estradiol levels.
Main Results:
- 62% of women experienced bleeding within the first 6 months of HRT.
- Shorter postmenopausal duration (≤24 months) significantly increased bleeding risk (RR 8.2).
- Higher pretreatment endometrial thickness (>5 mm) and serum estradiol levels (>25 pg/mL) were associated with bleeding in women with longer postmenopausal duration (>24 months).
Conclusions:
- Postmenopausal duration, endometrial thickness, and estradiol levels are key factors predicting early endometrial bleeding on continuous HRT.
- Identifying at-risk women allows for personalized HRT management and monitoring.